Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Next Previous
X
Search
Trial Profile

A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ-78278343 (Primary) ; JNJ-78278343 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 14 Aug 2024 Planned End Date changed from 15 Feb 2026 to 16 Feb 2026.
    • 26 Jul 2024 Planned End Date changed from 15 Nov 2025 to 15 Feb 2026.
    • 18 Jun 2024 Planned number of patients changed from 165 to 260.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top